Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

Author's Avatar
Jul 07, 2022
  • DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications
  • Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma